Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Early Release of Clinical Research Results May Prove Harmful

By HospiMedica staff writers
Posted on 22 Dec 2000
A study suggests that when medical trial results are released prior to journal publication, doctors may use the data to make changes in their practice--changes that may be harmful to some patients and may not agree with the detailed results later published in a peer-reviewed journal. More...
The study was conducted by researchers at the U.S. Agency for Healthcare Research and Quality (AHRQ), Yale University (New Haven, CT, USA), and Johns Hopkins University (Baltimore, MD, USA). The research was reported in the December 13 issue of The Journal of the American Medical Association (JAMA). Scientists and journal editors have long debated whether it is in the public's best interest to release the results of clinical trials prior to publication.

In the study, the researchers tracked the use of carotid endarterectomy (CEA) in two clinical trials. Both trials had been halted early, as potentially life-saving benefits of CEA were shown, and clinical alerts disseminated this information to doctors prior to journal publication. The alerts explained the findings of the study, but cautioned doctors that the trial included only patients under 80 and that the trials were conducted at medical centers with documented expertise in CEA.

After the alerts were released, there was a substantial increase in CEA use, about 18% over the six-month period following the first alert but then diminishing to only 0.5% after the findings were published. Following release in 1994 of the clinical alert on the second trial, the rate of use increased 42% over the next seven months. After the findings were published in 1995, however, the rate of use decreased 0.3%.

The study also found that the use of CEA after each alert was greater among patients over 80, despite the fact that such patients would not have been eligible for the trials. In contrast, following publication of the trial findings, there was a greater decrease among those 80 and older. Despite the warnings in the alerts, the researchers also found that many patients were referred to hospitals with less experience in the use of CEA than those in the trials.

"Future research could focus on how clinical alerts--the means used for alerting clinicians early to trial findings--might be structured to preserve their advantage while avoiding any potential downside,” said AHRQ researcher, Claudia Steiner, M.D., a coauthor of the study.

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.